

Criteria for the classification of monoclonal gammopath disorders: a report of the International Myeloma Worki

British Journal of Haematology
121, 749-57

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2010, 4, 182.	1.1	1
2	ecancermedalscience. Ecancermedalscience, 2013, 7, 331.	1.1	2
3	Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia, 2004, 18, 1879-1882.	7.2	73
6	Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein. Annals of Hematology, 2004, 83, 658-60.	1.8	4
7	Non-secretory Multiple Myeloma with Azurophilic Granules and Vacuoles: An Immunological and Ultrastructural Study. Internal Medicine, 2004, 43, 590-594.	0.7	4
8	Serum Levels of Free Light Chain before and after Chemotherapy in Primary Systemic AL Amyloidosis. Internal Medicine, 2005, 44, 428-433.	0.7	24
9	Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. Blood, 2005, 105, 4836-4844.	1.4	61
10	Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia, 2005, 19, 449-455.	7.2	83
11	Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma. Annals of Hematology, 2005, 84, 19-24.	1.8	7
12	Novel therapy in multiple myeloma. Investigational New Drugs, 2005, 23, 411-415.	2.6	7

13

#	ARTICLE	IF	CITATIONS
21	Clinical implication of centrosome amplification in plasma cell neoplasm. <i>Blood</i> , 2006, 107, 3669-3675.	1.4	90
22	International uniform response criteria for multiple myeloma. <i>Leukemia</i> , 2006, 20, 1467-1473.	7.2	2,332
23	From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature. <i>Clinical Rheumatology</i> , 2006, 25, 3-15.	2.2	26
24	Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. <i>Skeletal Radiology</i> , 2006, 35, 632-640.	2.0	116
25	Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Current Treatment Options in Oncology</i> , 2006, 7, 237-245.	3.0	14
26	Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. <i>BMC Cancer</i> , 2006, 6, 118.	2.6	164
27	Multiple Myeloma. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2533-2545.	6.1	137
28	Measurement of serum monoclonal components: comparison between densitometry and capillary zone electrophoresis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 609-11.	2.3	23
29	Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 722-725.	4.3	14
30	Monoclonal gammopathy in systemic lupus erythematosus. <i>Lupus</i> , 2007, 16, 426-429.	1.6	50
31	Body Mass Index, Physical Activity, and Risk of Multiple Myeloma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1474-1478.	2.5	79
32	Successful Treatment of Extramedullary Plasmacytoma of the Carvenous Sinus Using a Combination of Intermediate Dose of Thalidomide and Dexamethasone. <i>Acta Haematologica</i> , 2007, 117, 20-23.	1.4	15
33	Acquired Fanconi Syndrome with Osteomalacia Secondary to Monoclonal Gammopathy of Undetermined Significance. <i>Internal Medicine</i> , 2007, 46, 241-245.	0.7	11
35	Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry. <i>Human Pathology</i> , 2007, 38, 1779-1787.	2.0	55
36	Solitary plasmacytoma of bone in two successfully treated cats. <i>Journal of Feline Medicine and Surgery</i> , 2007, 9, 72-77.	1.6	10
37	Retrospective study of monoclonal gammopathies detected in the clinical laboratory of a Spanish healthcare district: 14-year series. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 190-6.	2.3	14
38	Urine proteomics: the present and future of measuring urinary protein components in disease. <i>Cmaj</i> , 2007, 177, 361-368.	2.0	183
39	Genetic events in the pathogenesis of multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 571-596.	1.7	154

#	ARTICLE	IF	CITATIONS
40	Therapy with Bortezomib plus Dexamethasone Induces Osteoblast Activation in Responsive Patients with Multiple Myeloma. <i>International Journal of Hematology</i> , 2007, 86, 180-185.	1.6	50
41	PET/CT and MR imaging in myeloma. <i>Skeletal Radiology</i> , 2007, 36, 5-16.	2.0	69
42	Multiple Myeloma Presenting with Malabsorption. <i>Digestive Diseases and Sciences</i> , 2007, 52, 1851-1854.	2.3	2
43	In vivo quantification of response to treatment in patients with multiple myeloma by 1H magnetic resonance spectroscopy of bone marrow. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2007, 20, 93-101.	2.0	25
44	Deposition-associated diseases related with a monoclonal compound. <i>Clinical and Translational Oncology</i> , 2007, 9, 777-783.	2.4	1
45	Secondary contributors to bone loss in osteoporosis related hip fractures. <i>Osteoporosis International</i> , 2008, 19, 991-999.	3.1	60
46	Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay. <i>Neuroradiology</i> , 2008, 50, 665-674.	2.2	116
47	Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. <i>Annals of Hematology</i> , 2008, 87, 439-449.	1.8	88
48	Thirty patients with primary plasma cell leukemia: a single center experience. <i>Medical Oncology</i> , 2008, 25, 154-160.	2.5	37
49	Extramedullary plasmacytomas in the head and neck region. <i>European Archives of Oto-Rhino-Laryngology</i> , 2008, 265, 1417-1423.	1.6	51
50	Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. <i>BMC Nephrology</i> , 2008, 9, 11.	1.8	159
51	Immunophenotypic studies of monoclonal gammopathy of undetermined significance. <i>BMC Clinical Pathology</i> , 2008, 8, 13.	1.8	24
52	European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial. <i>Trials</i> , 2008, 9, 55.	1.6	90
53	AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies. <i>Cancer Cell</i> , 2008, 13, 167-180.	16.8	322
54	MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 1285-1290.	7.1	235
55	JAK2V617F-Positive Essential Thrombocythemia and Multiple Myeloma with IGH/CCND1 Gene Translocation Coexist, but Originate from Separate Clones. <i>Acta Haematologica</i> , 2008, 120, 177-181.	1.4	15
56	Current Trends in Multiple Myeloma Management. <i>Journal of International Medical Research</i> , 2008, 36, 371-386.	1.0	5
57	Vertebroplasty in Multiple Myeloma: Outcomes in a Large Patient Series. <i>American Journal of Neuroradiology</i> , 2008, 29, 642-648.	2.4	126

#	ARTICLE	IF	CITATIONS
58	Systemic AL Amyloidosis Mimicking Rheumatoid Arthritis. Internal Medicine, 2008, 47, 1133-1138.	0.7	25
59	Long-term Follow-up of Plasma Cells in Bone Marrow and Serum Free Light Chains in Primary Systemic AL Amyloidosis. Internal Medicine, 2008, 47, 1783-1790.	0.7	11
60	Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood, 2008, 111, 785-789.	1.4	355
61	Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood, 2008, 112, 3582-3586.	1.4	170
62	Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood, 2008, 112, 3122-3125.	1.4	90
63	A 37-year-old Man Presenting with a Chief Complaint of Numbness in Both Hands. The Journal of the Japanese Society of Internal Medicine, 2008, 97, 479-480.	0.0	0
64	Therapeutic Outcome of Cyclic VAD (Vincristine, Doxorubicin and Dexamethasone) Therapy in Primary Systemic AL Amyloidosis Patients. Internal Medicine, 2008, 47, 1517-1522.	0.7	8
65	Extramedullary Pasmacytoma of the Epipharynx: A Case Report. Practica Otologica, 2008, 101, 445-452.	0.0	4
66	MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND SMOLDERING MULTIPLE MYELOMA. , 0, , 164-181.		0
67	The lymphomas and myeloma. , 0, , 347-369.		0
68	A Case of Cardiac Dysfunction Associated with Monoclonal Gammopathy of Undetermined Significance. Journal of Korean Medical Science, 2009, 24, 354.	2.5	1
69	Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance. Haematologica, 2009, 94, 1179-1181.	3.5	14
70	Insulin-like Growth Factor-1- and Interleukin-6-related Gene Variation and Risk of Multiple Myeloma: Table 1.. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 282-288.	2.5	37
71	Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood, 2009, 113, 5412-5417.	1.4	904
72	Serum Protein Electrophoresis: An Underused but Very Useful Test. Digestion, 2009, 79, 203-210.	2.3	74
73	Screening Panels for Detection of Monoclonal Gammopathies. Clinical Chemistry, 2009, 55, 1517-1522.	3.2	268
74	Nonsecretory multiple myeloma. Indian Journal of Orthopaedics, 2009, 43, 408.	1.1	17
75	Multiple Myeloma in Chronic Kidney Disease. Nephron Clinical Practice, 2009, 111, c7-c11.	2.3	12

#	ARTICLE	IF	CITATIONS
76	The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. <i>American Journal of Hematology</i> , 2009, 84, 208-214.	4.1	146
77	Multiple Myeloma. <i>Current Problems in Cancer</i> , 2009, 33, 7-64.	2.0	64
78	A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: I^{22} -microglobulin associated with time to progression. <i>International Journal of Hematology</i> , 2009, 89, 342-347.	1.6	9
79	Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. <i>International Journal of Hematology</i> , 2009, 89, 259-268.	1.6	31
80	Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. <i>Annals of Hematology</i> , 2009, 88, 1161-1168.	1.8	120
81	Extramedullary myeloma in an HIV-seropositive subject. Literature review and report of an unusual case. <i>Head & Face Medicine</i> , 2009, 5, 4.	2.1	12
82	Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. <i>British Journal of Haematology</i> , 2009, 144, 86-94.	2.5	220
83	Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. <i>Leukemia</i> , 2009, 23, 3-9.	7.2	1,000
84	Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. <i>Leukemia Research</i> , 2009, 33, 1475-1480.	0.8	75
85	Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. <i>Haematologica</i> , 2009, 94, 1599-1602.	3.5	92
86	IgM Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 17-18.	1.4	50
87	Novel Aspects Pertaining to the Relationship of Waldenström's Macroglobulinemia, IgM Monoclonal Gammopathy of Undetermined Significance, Polyclonal Gammopathy, and Hypoglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 19-22.	1.4	25
88	Treatment of Multiple Myeloma: A Comprehensive Review. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 278-288.	1.4	135
89	Frontal skull craniotomy combined with moderate-dose radiotherapy effectively ameliorate a rare case of non-secretory, multiple myeloma with orbital involvement. <i>World Journal of Surgical Oncology</i> , 2009, 7, 86.	1.9	2
90	Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. <i>Mayo Clinic Proceedings</i> , 2009, 84, 1095-1110.	3.0	389
91	Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β -Induced Interleukin 6 Production and the Myeloma Proliferative Component. <i>Mayo Clinic Proceedings</i> , 2009, 84, 114-122.	3.0	236
92	Plasma Cell Leukemia Maintaining Complete Remission by Syngeneic Stem Cell Transplantation Combined with Low-Dose Thalidomide Maintenance Therapy. <i>Internal Medicine</i> , 2009, 48, 1833-1835.	0.7	3
93	The significance of monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2009, 94, 1641-1644.	3.5	21

#	ARTICLE	IF	CITATIONS
94	Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. <i>Blood</i> , 2009, 113, 6386-6391.	1.4	137
95	Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. <i>Blood</i> , 2009, 114, 791-795.	1.4	133
96	Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. <i>Haematologica</i> , 2009, 94, 1714-1720.	3.5	95
97	Nodal and Extranodal Plasmacytomas Expressing Immunoglobulin A. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1425-1435.	3.7	25
98	Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. <i>Blood</i> , 2010, 115, 1185-1193.	1.4	66
99	Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. <i>Blood</i> , 2010, 116, 1056-1059.	1.4	137
100	Kidney disease associated with plasma cell dyscrasias. <i>Blood</i> , 2010, 116, 1397-1404.	1.4	50
101	Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. <i>Blood</i> , 2010, 116, 2019-2025.	1.4	59
102	Racial disparities in incidence and outcome in multiple myeloma: a population-based study. <i>Blood</i> , 2010, 116, 5501-5506.	1.4	308
103	A Rare Masquerader of Lung Cancer: Nonsecretory Multiple Myeloma with Plasmacytoma of Bone Presenting as Acute Kidney Injury. <i>Internal Medicine</i> , 2010, 49, 2133-2135.	0.7	0
104	PET/CT in primary musculoskeletal tumours: a step forward. <i>European Radiology</i> , 2010, 20, 2959-2972.	4.5	30
105	Extramedullary manifestations of multiple myeloma in the thyroid gland and in the lungs: excellent response to therapy. <i>Annals of Hematology</i> , 2010, 89, 1183-1184.	1.8	3
107	Artifactual measurement of low serum HDL-cholesterol due to paraproteinemia. <i>Clinical Research in Cardiology</i> , 2010, 99, 599-602.	3.3	4
108	Methylation status of nine tumor suppressor genes in multiple myeloma. <i>International Journal of Hematology</i> , 2010, 91, 87-96.	1.6	36
109	Uncommon case of chronic myeloid leukemia with multiple myeloma. <i>International Journal of Hematology</i> , 2010, 91, 699-704.	1.6	26
110	Extramedullary plasmacytoma of the dura mimicking meningioma. <i>International Journal of Hematology</i> , 2010, 91, 731-732.	1.6	9
111	Prevalence, clinical aspects, and natural history of IgM MGUS. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S91-7.	1.5	20
112	Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or Tj ETQq1 1 0.784314 rgBT /Over	4.1	24

#	ARTICLE	IF	CITATIONS
113	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia, 2010, 24, 1121-1127.	7.2	677
114	Robert Arthur Kyle, MD: A Conversation with the Editor. Baylor University Medical Center Proceedings, 2010, 23, 400-418.	0.5	0
115	Multiple myeloma. Cancer Imaging, 2010, 10, 20-31.	2.8	29
116	A Case Study Progression to Multiple Myeloma. Clinical Journal of Oncology Nursing, 2010, 14, 419-422.	0.6	0
117	Multiple Myeloma Precursor Disease. JAMA - Journal of the American Medical Association, 2010, 304, 2397.	7.4	48
118	Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. Expert Review of Hematology, 2010, 3, 165-174.	2.2	13
119	Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations. Journal of Clinical Oncology, 2010, 28, 690-697.	1.6	101
120	Multiple myeloma presenting as CEA-producing rectal cancer. Rare Tumors, 2010, 2, 10-11.	0.6	4
121	Plasma cell leukemia. Haematologica, 2010, 95, 705-707.	3.5	15
122	Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: New Insights into Pathophysiology and Epidemiology. Hematology American Society of Hematology Education Program, 2010, 2010, 295-302.	2.5	25
123	Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Review of Molecular Diagnostics, 2010, 10, 465-480.	3.1	52
124	Plasma Cell Labeling Index in the Evaluation of Smoldering (Asymptomatic) Multiple Myeloma. Mayo Clinic Proceedings, 2010, 85, 300.	3.0	19
125	Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma. Mayo Clinic Proceedings, 2010, 85, 232-238.	3.0	69
126	Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review. Mayo Clinic Proceedings, 2010, 85, 933-942.	3.0	180
127	Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma. Diagnostic Pathology, 2010, 5, 30.	2.0	34
128	Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 248-257.	0.4	18
129	Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Practice and Research in Clinical Haematology, 2010, 23, 433-451.	1.7	101
130	Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet, The, 2010, 375, 1721-1728.	13.7	313

#	ARTICLE	IF	CITATIONS
131	Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. <i>Blood</i> , 2011, 118, 2985-2987.	1.4	35
132	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. <i>Blood</i> , 2011, 117, 5573-5581.	1.4	161
133	85-Year-Old Man With Epistaxis. <i>Mayo Clinic Proceedings</i> , 2011, 86, 344-347.	3.0	0
134	The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. <i>Blood</i> , 2011, 117, 5019-5032.	1.4	1,681
135	Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 593-603.	3.1	35
136	Myelomagenesis: Capturing Early Microenvironment Changes. <i>Seminars in Hematology</i> , 2011, 48, 13-21.	3.4	7
137	Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Man with Fragile X-associated Tremor/Ataxia Syndrome. <i>Case Reports in Genetics</i> , 2011, 2011, 1-5.	0.2	2
138	Myelomatous Pleural Effusion: A Case Series in a Single Institution and Literature Review. <i>Annals of Laboratory Medicine</i> , 2011, 31, 225-230.	2.5	27
139	Multiple Myeloma Presenting as Acute Renal Failure. <i>Baylor University Medical Center Proceedings</i> , 2011, 24, 302-305.	0.5	5
140	Fractal Characteristics of May-Grünwald-Giemsa Stained Chromatin Are Independent Prognostic Factors for Survival in Multiple Myeloma. <i>PLoS ONE</i> , 2011, 6, e20706.	2.5	50
141	Computational Modeling of Interactions between Multiple Myeloma and the Bone Microenvironment. <i>PLoS ONE</i> , 2011, 6, e27494.	2.5	37
142	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. <i>Blood</i> , 2011, 117, 4696-4700.	1.4	285
143	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	1.4	282
144	Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. <i>Blood</i> , 2011, 118, 2702-2707.	1.4	23
145	Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. <i>Blood</i> , 2011, 118, 1763-1765.	1.4	59
146	Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1 α levels in patients with MGUS. <i>Blood</i> , 2011, 118, 6529-6534.	1.4	62
148	Immunoglobulin D-Lambda Type Multiple Myeloma Presenting with FDG-PET/CT Negative Bone Marrow Involvement. <i>Internal Medicine</i> , 2011, 50, 1483-1487.	0.7	4
149	Successful Treatment of Immunoglobulin D Myeloma by Bortezomib and Dexamethasone Therapy. <i>Internal Medicine</i> , 2011, 50, 2653-2657.	0.7	3

#	ARTICLE	IF	CITATIONS
152	CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. <i>Haematologica</i> , 2011, 96, 1557-1559.	3.5	31
153	Hypergammaglobulinemia in an SIV-Infected Rhesus Macaque with a B-cell neoplasm with plasma cell differentiation. <i>Journal of Medical Primatology</i> , 2011, 40, 200-204.	0.6	0
154	Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. <i>Leukemia</i> , 2011, 25, 697-706.	7.2	75
155	Extramedullary Relapse in a Case of Multiple Myeloma Involving the Thyroid Cartilage: Case Report and Review of Literature. <i>Indian Journal of Surgical Oncology</i> , 2011, 2, 313-315.	0.7	8
156	Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma. <i>Investigational New Drugs</i> , 2011, 29, 175-181.	2.6	3
157	The Relationship Between Hypogammaglobulinemia, Monoclonal Gammopathy of Undetermined Significance and Humoral Immunodeficiency: a Case Series. <i>Journal of Clinical Immunology</i> , 2011, 31, 737-743.	3.8	15
158	Living with multiple myeloma: experiences of patients and their informal caregivers. <i>Supportive Care in Cancer</i> , 2011, 19, 101-111.	2.2	84
159	Impact of Radiotherapy on Pain Relief and Recalcification in Plasma Cell Neoplasms. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 114-119.	2.0	39
160	Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1046-1053.	6.4	79
161	The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma. <i>Skeletal Radiology</i> , 2011, 40, 843-847.	2.0	57
162	Renal disorder preceding multiple myeloma. <i>Medical Oncology</i> , 2011, 28, 199-201.	2.5	3
163	EBV-Positive Plasmacytoma of the Submandibular Gland—Report of a Rare Case with Molecular Genetic Characterization. <i>Head and Neck Pathology</i> , 2011, 5, 389-394.	2.6	14
164	Primary plasma cell leukemia followed by testicular plasmacytoma. <i>International Journal of Hematology</i> , 2011, 93, 224-227.	1.6	7
165	Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma. <i>International Journal of Hematology</i> , 2011, 93, 257-259.	1.6	4
166	Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. <i>International Journal of Hematology</i> , 2011, 93, 351-360.	1.6	19
167	Primary plasmacytoma of the testicle: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 494.	0.8	8
168	Plasma cell leukemia. <i>Blood Reviews</i> , 2011, 25, 107-112.	5.7	81
169	Abnormal radiological features in a multiple myeloma patient: a case report and radiological review of myelomas. <i>Dentomaxillofacial Radiology</i> , 2011, 40, 513-518.	2.7	26

#	ARTICLE	IF	CITATIONS
170	Current and future imaging modalities for multiple myeloma and its precursor states. <i>Leukemia and Lymphoma</i> , 2011, 52, 1630-1640.	1.3	27
171	Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes. <i>Clinics</i> , 2011, 66, 2055-2061.	1.5	14
172	Myeloma cells suppress osteoblasts through sclerostin secretion. <i>Blood Cancer Journal</i> , 2011, 1, e27-e27.	6.2	113
173	The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future. <i>Oncologist</i> , 2011, 16, 651-662.	3.7	62
174	A Case of Monoclonal Lymphoplasmacytosis of the Bone Marrow with IgM-Positive Russell Bodies. <i>Bone Marrow Research</i> , 2011, 2011, 1-3.	1.7	1
175	A Systematic Review on the Use of Bortezomib in Multiple Myeloma Patients with Renal Impairment: What Is the Published Evidence. <i>Acta Haematologica</i> , 2011, 126, 163-168.	1.4	15
176	Bilateral Crystalline Corneal Deposits as First Clinical Manifestation of Monoclonal Gammopathy: A Case Report. <i>Case Reports in Ophthalmology</i> , 2011, 2, 222-227.	0.7	12
177	Crescentic Glomerulonephritis in IgA Multiple Myeloma: A Case Report. <i>Nephron Extra</i> , 2011, 1, 69-72.	1.1	3
178	MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin. <i>Clinical Cancer Research</i> , 2011, 17, 4309-4319.	7.0	83
179	Polymyositis associated with non-secretory myeloma – a case report. <i>Australasian Medical Journal</i> , 2011, 4, 205-209.	0.1	2
180	Maintaining Bone Health in Patients With Multiple Myeloma. <i>Clinical Journal of Oncology Nursing</i> , 2011, 15, 9-23.	0.6	28
181	Diagnosis of Smoldering Multiple Myeloma. <i>New England Journal of Medicine</i> , 2011, 365, 474-475.	27.0	155
182	The Role of Serum Protein Electrophoresis in the Detection of Multiple Myeloma: An Experience of a Corporate Hospital. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2012, 6, 1458-61.	0.8	19
183	Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand. <i>Annals of Clinical Biochemistry</i> , 2012, 49, 242-256.	1.6	71
184	Assessing response of myeloma bone disease with diffusion-weighted MRI. <i>British Journal of Radiology</i> , 2012, 85, e1198-e1203.	2.2	128
185	Genomic analysis of high-risk smoldering multiple myeloma. <i>Haematologica</i> , 2012, 97, 1439-1443.	3.5	43
186	Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. <i>Leukemia</i> , 2012, 26, 1091-1097.	7.2	85
187	Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. <i>Leukemia</i> , 2012, 26, 609-614.	7.2	88

#	ARTICLE	IF	CITATIONS
188	Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation. <i>Leukemia</i> , 2012, 26, 2286-2296.	7.2	33
189	Increased Numbers of T Helper 17 Cells and the Correlation with Clinicopathological Characteristics in Multiple Myeloma. <i>Journal of International Medical Research</i> , 2012, 40, 556-564.	1.0	38
190	Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance. <i>OncoTargets and Therapy</i> , 2012, 5, 329.	2.0	23
191	The Role of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Evaluating the Response to Treatment in Patients with Multiple Myeloma. <i>International Journal of Molecular Imaging</i> , 2012, 2012, 1-6.	1.3	21
192	Laryngeal Involvement of Multiple Myeloma. <i>Case Reports in Oncological Medicine</i> , 2012, 2012, 1-3.	0.3	6
193	Plasmacytoma of the Nasolacrimal Duct Simulating Dacryocystitis: An Uncommon Presentation for Extramedullary Relapse of Multiple Myeloma. <i>Case Reports in Oncology</i> , 2012, 5, 119-124.	0.7	4
194	Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?. <i>Haematologica</i> , 2012, 97, 1608-1611.	3.5	17
196	A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. <i>Blood</i> , 2012, 120, 1801-1809.	1.4	393
197	How I treat plasma cell leukemia. <i>Blood</i> , 2012, 120, 2376-2389.	1.4	115
198	Treatment for Myeloma of the Spinal Lesions. <i>Orthopedics & Traumatology</i> , 2012, 61, 468-472.	0.1	0
199	Extramedullary involvement in multiple myeloma. <i>Haematologica</i> , 2012, 97, 1618-1619.	3.5	77
200	Prevalence and type of monoclonal gammopathy of undetermined significance in an apparently healthy Nigerian population: a cross sectional study. <i>BMC Blood Disorders</i> , 2012, 12, 7.	0.9	4
201	NF- κ B2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors. <i>BMC Cancer</i> , 2012, 12, 203.	2.6	4
202	Is fluorine-18-fluorodeoxyglucose positron emission tomography useful in monitoring the response to treatment in patients with multiple myeloma?. <i>International Journal of Hematology</i> , 2012, 96, 685-691.	1.6	22
203	The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. <i>Blood Cancer Journal</i> , 2012, 2, e96-e96.	6.2	70
204	Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma?. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 383-393.	2.2	8
205	Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation. <i>International Medical Case Reports Journal</i> , 2012, 5, 39.	0.8	0
206	Breast manifestations of systemic diseases. <i>International Journal of Women's Health</i> , 2012, 4, 35.	2.6	22

#	ARTICLE	IF	CITATIONS
207	Trends and outcomes of modern staging of solitary plasmacytoma of bone. American Journal of Hematology, 2012, 87, 647-651.	4.1	69
208	Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood, 2012, 119, 5359-5366.	1.4	68
210	Renal impairment in multiple myeloma: Presenting features in different departments. Journal of Huazhong University of Science and Technology [Medical Sciences], 2012, 32, 65-68.	1.0	2
211	Pancreatic Involvement by Plasma Cell Neoplasms. Journal of Gastrointestinal Cancer, 2012, 43, 157-167.	1.3	16
212	Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma. International Journal of Hematology, 2012, 95, 516-526.	1.6	15
213	Detection of serum tumor markers in multiple myeloma using the CLINPROT system. International Journal of Hematology, 2012, 95, 668-674.	1.6	16
214	Variations in Suppressor Molecule CTLA-4 Gene Are Related to Susceptibility to Multiple Myeloma in a Polish Population. Pathology and Oncology Research, 2012, 18, 219-226.	1.9	28
215	Plasma Cell Leukemia: Case Series From a Tertiary Center with Review of Literature. Indian Journal of Hematology and Blood Transfusion, 2012, 28, 10-14.	0.6	12
216	Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) imaging of multiple myeloma: initial clinical efficiency results. European Radiology, 2012, 22, 1114-1121.	4.5	26
217	Multiple myeloma: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2012, 87, 78-88.	4.1	120
218	Prevalence of monoclonal gammopathy of undetermined significance in Thailand. International Journal of Hematology, 2012, 95, 176-181.	1.6	24
219	Microscopic examination of bone marrow aspirates in malignant disorders of haematopoiesis: a comparison of two slide preparation techniques. Annals of Hematology, 2012, 91, 497-505.	1.8	5
220	Epigenetic inactivation of the MIR129-2 in hematological malignancies. Journal of Hematology and Oncology, 2013, 6, 16.	17.0	59
221	Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms. Biomarker Research, 2013, 1, 8.	6.8	31
222	Bortezomib, Dexamethasone, and High-Dose Melphalan as Conditioning for Stem Cell Transplantation in Young Japanese Multiple Myeloma Patients: A Pilot Study. Indian Journal of Hematology and Blood Transfusion, 2013, 29, 147-151.	0.6	3
223	Cranial Plasmacytoma: A Case Series and Review of the Literature. Indian Journal of Hematology and Blood Transfusion, 2013, 29, 43-47.	0.6	7
226	Smoldering multiple myeloma requiring treatment: time for a new definition?. Blood, 2013, 122, 4172-4181.	1.4	70
227	Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma. Annals of Pharmacotherapy, 2013, 47, 56-62.	1.9	55

#	ARTICLE	IF	CITATIONS
229	New Approaches to Smoldering Myeloma. Current Hematologic Malignancy Reports, 2013, 8, 270-276.	2.3	17
230	Clinical interest of bone marrow aspiration in rheumatology: a practice-based observational study of 257 bone marrow aspirations. Clinical Rheumatology, 2013, 32, 115-121.	2.2	3
231	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia, 2013, 27, 780-791.	7.2	294
232	Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia, 2013, 27, 1738-1744.	7.2	194
233	A case of multiple myeloma presenting as scalp swelling with intracranial extension. Journal of Neurosciences in Rural Practice, 2013, 04, 445-448.	0.8	6
234	Multiple Extramedullary Plasmacytoma with Lytic Bony Lesions: A Rare Case Report. Case Reports in Medicine, 2013, 2013, 1-3.	0.7	5
235	Diagnosis and Treatment of Bone Disease in Multiple Myeloma: Spotlight on Spinal Involvement. Scientifica, 2013, 2013, 1-12.	1.7	61
236	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. Journal of Clinical Oncology, 2013, 31, 4319-4324.	1.6	193
237	Precursors to Lymphoproliferative Malignancies. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 533-539.	2.5	15
238	Multiple myeloma in a kidney transplanted patient primarily diagnosed with monoclonal gammopathy of unknown significance (MGUS)-related nephropathy. CKJ: Clinical Kidney Journal, 2013, 6, 445-446.	2.9	0
239	Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma. Clinical Cancer Research, 2013, 19, 2248-2256.	7.0	78
240	Kidney Disease and Multiple Myeloma. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 2007-2017.	4.5	125
241	Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation. ISRN Hematology, 2013, 2013, 1-7.	1.6	6
242	Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S7764.	1.3	22
243	Cyclin D1 expression in multiple myeloma by immunohistochemistry: Case series of 14 patients and literature review. Indian Journal of Medical and Paediatric Oncology, 2013, 34, 283-291.	0.2	12
244	Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17,315 patients. Leukemia, 2013, 27, 1391-1393.	7.2	45
245	Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia, 2013, 27, 941-946.	7.2	201
246	High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia, 2013, 27, 680-685.	7.2	138

#	ARTICLE	IF	CITATIONS
247	Solitary plasmacytoma of the skull: Two case reports. <i>Oncology Letters</i> , 2013, 5, 479-482.	1.8	8
248	Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. <i>Blood</i> , 2013, 121, 4647-4654.	1.4	128
249	Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. <i>Blood</i> , 2013, 122, 3122-3128.	1.4	126
250	Multiple Myeloma Masquerades as Rheumatic Diseases. <i>Proceedings of Singapore Healthcare</i> , 2013, 22, 64-69.	0.6	3
251	The Spectrum of Type I Cryoglobulinemia Vasculitis. <i>Medicine (United States)</i> , 2013, 92, 61-68.	1.0	150
252	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. , 0, , 121-133.		2
253	Therapeutic Effects of Lenalidomide on Hemorrhagic Intestinal Myeloma-associated AL Amyloidosis. <i>Internal Medicine</i> , 2013, 52, 1101-1105.	0.7	4
254	Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. <i>Cancer Management and Research</i> , 2013, 5, 225.	1.9	22
255	BM mesenchymal stromal cellâ€‘derived exosomes facilitate multiple myeloma progression. <i>Journal of Clinical Investigation</i> , 2013, 123, 1542-1555.	8.2	661
256	Data quality of the monoclonal gammopathy of undetermined significance diagnosis in a hospital registry. <i>Clinical Epidemiology</i> , 2013, 5, 321.	3.0	5
257	Factitious Biochemical Reports which are Caused Due to Paraproteinaemia in Multiple Myeloma â€‘ A Case Report. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2013, 7, 350-2.	0.8	4
258	Frequent Occurrence of Highly Expanded but Unrelated B-Cell Clones in Patients with Multiple Myeloma. <i>PLoS ONE</i> , 2013, 8, e64927.	2.5	13
259	Occurrence of multiple myeloma in the head and neck: a report of two cases. <i>Journal of the Korean Association of Oral and Maxillofacial Surgeons</i> , 2013, 39, 139.	0.8	2
260	Multiple Myeloma: An Update. <i>Oman Medical Journal</i> , 2013, 28, 3-11.	1.0	33
261	Multiple solitary plasmacytoma with multifocal bone involvement. First clinical case report in a uraemic patient. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013009157-bcr2013009157.	0.5	7
262	Paraneoplastic pemphigus presenting with a single oral lesion. <i>BMJ Case Reports</i> , 2013, 2013, bcr2012007771-bcr2012007771.	0.5	7
263	Ilmaquinone and Ethylsmenoquinone, Marine Sponge Metabolites, Suppress the Proliferation of Multiple Myeloma Cells by Down-Regulating the Level of β -Catenin. <i>Marine Drugs</i> , 2014, 12, 3231-3244.	4.6	32
264	Letter to the Editor Amyloidosis of the head and neck: a clinicopathological study of cases with long term follow-up. <i>Archives of Medical Science</i> , 2014, 4, 846-852.	0.9	13

#	ARTICLE	IF	CITATIONS
265	Clinicopathological significance and potential drug target of p15INK4B in multiple myeloma. Drug Design, Development and Therapy, 2014, 8, 2129.	4.3	12
266	Extramedullary Plasmacytoma of Gingiva and Soft Tissue in Neck. Journal of Clinical and Diagnostic Research JCDR, 2014, 8, ZD16-8.	0.8	2
267	Helicobacter pylori-negative Russell body gastritis: does the diagnosis call for screening for plasmacytic malignancies, especially multiple myeloma?. BMJ Case Reports, 2014, 2014, bcr2013202672-bcr2013202672.	0.5	10
269	The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma. European Radiology, 2014, 24, 2754-2765.	4.5	54
270	The role of radiotherapy in the management of POEMS syndrome. Radiation Oncology, 2014, 9, 265.	2.7	18
271	Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. Leukemia, 2014, 28, 413-416.	7.2	24
272	Determination of Prognostic Factors in Japanese Patients With Advanced Gastric Cancer Using the Data From a Randomized Controlled Trial, Japan Clinical Oncology Group 9912. Oncologist, 2014, 19, 358-366.	3.7	54
273	Immune Defects in the Risk of Infection and Response to Vaccination in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. Frontiers in Immunology, 2014, 5, 257.	4.8	39
274	Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future. BioMed Research International, 2014, 2014, 1-7.	1.9	17
275	How I treat smoldering multiple myeloma. Blood, 2014, 124, 3380-3388.	1.4	41
276	Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells. BioMed Research International, 2014, 2014, 1-7.	1.9	12
277	Local Renin-Angiotensin System in Normal Hematopoietic and Multiple Myeloma-Related Progenitor Cells. Turkish Journal of Haematology, 2014, 31, 136-142.	0.5	6
278	Solitary bone plasmacytoma: An interesting case report with unusual clinico-cytological features. Journal of Cytology, 2014, 31, 158.	0.6	8
279	Pathogenesis of Renal Failure in Multiple Myeloma: Any Role of Contrast Media?. BioMed Research International, 2014, 2014, 1-10.	1.9	14
280	Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica, 2014, 99, 155-162.	3.5	23
281	Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica, 2014, 99, 1365-1372.	3.5	65
282	FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells. Cancer Immunology, Immunotherapy, 2014, 63, 1189-1197.	4.2	65
283	Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease. International Journal for Numerical Methods in Biomedical Engineering, 2014, 30, 1085-1102.	2.1	21

#	ARTICLE	IF	CITATIONS
284	Common community-acquired infections and subsequent risk of multiple myeloma: A population-based study. <i>International Journal of Cancer</i> , 2014, 134, 1734-1740.	5.1	15
285	Quantification of peptides from immunoglobulin constant and variable regions by LC-MS/MS for assessment of multiple myeloma patients. <i>Proteomics - Clinical Applications</i> , 2014, 8, 783-795.	1.6	33
286	Minimal Change Nephrotic Syndrome Associated With Non-Hodgkin Lymphoid Disorders. <i>Medicine (United States)</i> , 2014, 93, 350-358.	1.0	36
287	Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma. <i>Cancer Science</i> , 2014, 105, 1496-1502.	3.9	54
288	A rare condition: IgE type monoclonal gammopathy of undetermined significance. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, e183-5.	2.3	5
289	Regular Aspirin Use and Risk of Multiple Myeloma: A Prospective Analysis in the Health Professionals Follow-up Study and Nurses' Health Study. <i>Cancer Prevention Research</i> , 2014, 7, 33-41.	1.5	27
290	The Genetic Architecture of Multiple Myeloma. <i>Advances in Hematology</i> , 2014, 2014, 1-16.	1.0	79
291	Maxillary pain is the first indication of the presence of multiple myeloma: A case report. <i>Molecular and Clinical Oncology</i> , 2014, 2, 59-64.	1.0	12
292	Extramedullary plasmacytoma in the carotid space: Expanding the differential diagnosis. <i>Indian Journal of Radiology and Imaging</i> , 2014, 24, 410.	0.8	1
293	Solitary Bone Plasmacytoma Progressing into Retroperitoneal Plasma Cell Myeloma with No Related End Organ or Tissue Impairment: A Case Report and Review of the Literature. <i>Turkish Journal of Haematology</i> , 2014, 31, 286-289.	0.5	4
294	Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-6.	1.9	12
295	Analysis of patients with λ -heavy chain disease by the heavy/light chain and free light chain assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 665-9.	2.3	10
296	Empfehlungen zur Häufigkeit der Anforderung von Laboruntersuchungen. <i>Laboratoriums Medizin</i> , 2014, 38, 231-238.	0.6	1
297	Management of multiple myeloma in older people. <i>Reviews in Clinical Gerontology</i> , 2014, 24, 173-181.	0.5	0
298	Intracloonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. <i>Leukemia</i> , 2014, 28, 384-390.	7.2	252
299	How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 303-309.	2.5	10
300	^{11}C -Acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 41-49.	6.4	38
301	The multiple oral presentations of multiple myeloma. <i>Supportive Care in Cancer</i> , 2014, 22, 259-267.	2.2	28

#	ARTICLE	IF	CITATIONS
302	Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2014, 28, 174-178.	7.2	66
303	Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. <i>Leukemia</i> , 2014, 28, 1725-1735.	7.2	221
304	The impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy. <i>International Journal of Hematology</i> , 2014, 99, 288-295.	1.6	20
305	Detection of monoclonal IGH rearrangements in circulating cells from healthy first-degree relatives of patients with multiple myeloma. <i>Medical Oncology</i> , 2014, 31, 900.	2.5	2
306	PET/CT studies of multiple myeloma using 18â€‰F-FDG and 18â€‰F-NaF: comparison of distribution patterns and tracersâ€™ pharmacokinetics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1343-1353.	6.4	55
307	Confocal microscopy in a case of crystalline keratopathy in a patient with smouldering multiple myeloma. <i>International Ophthalmology</i> , 2014, 34, 651-654.	1.4	10
308	Myeloma in Scar Tissue - An Underreported Phenomenon or an Emerging Entity in the Novel Agents' Era? A Single Center Series. <i>Acta Haematologica</i> , 2014, 132, 39-44.	1.4	15
309	Serum-free light-chain assay: clinical utility and limitations. <i>Annals of Clinical Biochemistry</i> , 2014, 51, 528-542.	1.6	59
310	Biologic Frontiers in Multiple Myeloma: From Biomarker Identification to Clinical Practice. <i>Clinical Cancer Research</i> , 2014, 20, 804-813.	7.0	29
311	Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. <i>Blood</i> , 2014, 123, 338-345.	1.4	105
312	Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. <i>Lancet Haematology</i> , 2014, 1, e28-e36.	4.6	40
313	Early lymphoid lesions: conceptual, diagnostic and clinical challenges. <i>Haematologica</i> , 2014, 99, 1421-1432.	3.5	50
314	Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival. <i>BMC Cancer</i> , 2014, 14, 462.	2.6	30
316	Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen cases. <i>International Journal of Hematology</i> , 2014, 99, 721-725.	1.6	10
317	Clinical Manifestations at Diagnosis in Japanese Patients with Systemic AL Amyloidosis: A Retrospective Study of 202 Cases with a Special Attention to Uncommon Symptoms. <i>Internal Medicine</i> , 2014, 53, 403-412.	0.7	31
318	Hematologic manifestations of <i>Helicobacter pylori</i> infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 12818.	3.3	62
319	Imaging of multiple myeloma: Current concepts. <i>World Journal of Orthopedics</i> , 2014, 5, 272.	1.8	67
320	A Case of Laryngo-tracheal Involvement of Multiple Myelomas. <i>Practica Otologica</i> , Supplement, 2014, 138, 88-89.	0.0	0

#	ARTICLE	IF	CITATIONS
321	Diffuse Parenchymal Pulmonary Amyloidosis Showing an Objective Response to Bortezomib-based Chemotherapy. Internal Medicine, 2014, 53, 1809-1812.	0.7	6
322	Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. Blood, 2014, 123, 647-649.	1.4	32
323	Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood, 2014, 123, 78-85.	1.4	173
324	CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease. Blood, 2014, 124, 2051-2060.	1.4	26
325	A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood, 2014, 124, 899-906.	1.4	73
326	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood, 2014, 124, 907-912.	1.4	111
327	Curing myeloma at last: defining criteria and providing the evidence. Blood, 2014, 124, 3043-3051.	1.4	194
328	Unveiling Skeletal Fragility in Patients Diagnosed With MGUS: No Longer a Condition of Undetermined Significance?. Journal of Bone and Mineral Research, 2014, 29, 2529-2533.	2.8	42
329	Comparing Five Diagnostic Criteria for Multiple Myeloma: A Retrospective Study of 227 Cases. Tumori, 2014, 100, 207-213.	1.1	4
330	Bone Disease in Multiple Myeloma: Pathophysiology and Management. Cancer Growth and Metastasis, 2014, 7, CGM.S16817.	3.5	131
331	The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica, 2014, 99, 629-637.	3.5	61
332	Neuroimaging of Plasmacytoma. Neuroradiology Journal, 2014, 27, 431-437.	1.2	24
333	Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma. Medicine (United States), 2015, 94, e2305.	1.0	43
334	Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing. Blood, 2015, 126, 1443-1451.	1.4	78
336	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica, 2015, 100, 1214-1221.	3.5	44
337	CD4+CD25+ cells in multiple myeloma related renal impairment. Scientific Reports, 2015, 5, 16565.	3.3	5
338	Myelomatous Pleural Effusion Presenting with Extreme Hyperferritinemia and Severe Inflammatory Response. Case Reports in Oncology, 2015, 8, 349-355.	0.7	2
339	Correlation between microRNA-21 and sprouty homolog 2 gene expression in multiple myeloma. Molecular Medicine Reports, 2015, 11, 4220-4224.	2.4	8

#	ARTICLE	IF	CITATIONS
341	Recommendations for the frequency of ordering laboratory testing. <i>Laboratoriums Medizin</i> , 2015, 38, .	0.6	0
342	Unusual coexistence of extramedullary plasmacytoma and nasopharyngeal carcinoma in nasopharynx. <i>Diagnostic Pathology</i> , 2015, 10, 170.	2.0	9
343	Bone Cement Augmentation Procedures for Spinal Pathologic Fractures by Multiple Myeloma. <i>Journal of Korean Medical Science</i> , 2015, 30, 88.	2.5	20
344	Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors. <i>Turkish Journal of Haematology</i> , 2015, 32, 234-242.	0.5	23
345	A case of solitary plasmacytoma of bone arising in the mandible. <i>Nihon Koku Geka Gakkai Zasshi</i> , 2015, 61, 463-468.	0.0	2
346	The Use of MAGE C1 and Flow Cytometry to Determine the Malignant Cell Type in Multiple Myeloma. <i>PLoS ONE</i> , 2015, 10, e0120734.	2.5	14
347	Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma. <i>PLoS ONE</i> , 2015, 10, e0127022.	2.5	18
348	Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study. <i>PLoS ONE</i> , 2015, 10, e0137552.	2.5	7
349	A Rare Case of Nonsecretory Multiple Myeloma in Lagos, Nigeria: A Case Report and Literature Review. <i>Case Reports in Medicine</i> , 2015, 2015, 1-3.	0.7	2
350	Maxillary Swelling as the First Evidence of Multiple Myeloma. <i>Case Reports in Dentistry</i> , 2015, 2015, 1-5.	0.5	7
351	Smoldering Multiple Myeloma. <i>BioMed Research International</i> , 2015, 2015, 1-7.	1.9	3
352	High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity. <i>Tumor Biology</i> , 2015, 36, 8491-8497.	1.8	8
353	Treatment for IgG and IgA paraproteinaemic neuropathy. <i>The Cochrane Library</i> , 2019, 2019, CD005376.	2.8	23
354	Inter-observer agreement for the evaluation of bone involvement on Whole Body Low Dose Computed Tomography (WBLDCT) in Multiple Myeloma (MM). <i>European Radiology</i> , 2015, 25, 3382-3389.	4.5	5
355	t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. <i>Blood Cancer Journal</i> , 2015, 5, e285-e285.	6.2	33
356	A voluminous mass as an initial clinical symptom of multiple myeloma: A case report. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 1689-1691.	1.8	1
357	Dilemmas in Treating Smoldering Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2015, 33, 115-123.	1.6	19
358	A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. <i>Leukemia</i> , 2015, 29, 218-229.	7.2	55

#	ARTICLE	IF	CITATIONS
359	GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. <i>Haematologica</i> , 2015, 100, 377-384.	3.5	64
360	Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study. <i>Lancet Haematology</i> , 2015, 2, e30-e36.	4.6	54
361	Comparison of 11C-4 β -thiothymidine, 11C-methionine, and 18F-FDG PET/CT for the detection of active lesions of multiple myeloma. <i>Annals of Nuclear Medicine</i> , 2015, 29, 224-232.	2.2	42
362	Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results Medicare Database. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1823-1829.	2.0	30
363	Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. <i>Kidney International</i> , 2015, 88, 1135-1143.	5.2	104
364	Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. <i>Leukemia and Lymphoma</i> , 2015, 56, 1416-1424.	1.3	23
365	Bilateral pleural effusion as an initial manifestation of multiple myeloma: A case report and literature review. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 1040-1042.	1.8	8
366	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. <i>Nature Communications</i> , 2015, 6, 7539.	12.8	38
367	Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. <i>Oncotarget</i> , 2015, 4, e1008850.	4.6	27
368	Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging. <i>Acta Radiologica</i> , 2015, 56, 733-738.	1.1	26
369	Cisplatin-induced inhibition of mTOR pathway enables stress-induced autophagy. <i>EMBO Journal</i> , 2015, 34, 1214-1230.	7.8	66
370	MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management. <i>European Journal of Endocrinology</i> , 2015, 173, R131-R151.	3.7	215
371	BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. <i>Blood Cancer Journal</i> , 2015, 5, e299-e299.	6.2	36
372	The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs. <i>Bone Marrow Transplantation</i> , 2015, 50, 822-828.	2.4	17
373	The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma. <i>Leukemia</i> , 2015, 29, 1713-1720.	7.2	6
374	Current therapeutic strategies for multiple myeloma. <i>International Journal of Clinical Oncology</i> , 2015, 20, 423-430.	2.2	22
375	Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 669-678.	2.8	36
376	Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance. <i>Blood Cancer Journal</i> , 2015, 5, e345-e345.	6.2	23

#	ARTICLE	IF	CITATIONS
377	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.	3.5	289
378	Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation. <i>Blood Cancer Journal</i> , 2015, 5, e294-e294.	6.2	5
379	Clinical and prognostic significance of bone marrow abnormalities in the appendicular skeleton detected by low-dose whole-body multidetector computed tomography in patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2015, 5, e329-e329.	6.2	23
380	Immunoglobulin IgA, IgD, IgG, IgM and IgG subclass reference values in adults. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, e359-61.	2.3	25
381	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1413-1417.	2.0	5
382	SnapShot: Multiple Myeloma. <i>Cancer Cell</i> , 2015, 28, 678-678.e1.	16.8	31
383	The road to cure in multiple myeloma starts with smoldering disease. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 653-661.	0.8	6
384	Multiple myeloma maintenance therapy: A review of the pharmacologic treatment. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 36-51.	0.9	19
385	Classifying ultra-high risk smoldering myeloma. <i>Leukemia</i> , 2015, 29, 751-753.	7.2	37
386	18F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. <i>Clinical and Experimental Medicine</i> , 2015, 15, 1-18.	3.6	60
387	Potential role of exosome-associated microRNA panels and <i>in vivo</i> environment to predict drug resistance for patients with multiple myeloma. <i>Oncotarget</i> , 2016, 7, 30876-30891.	1.8	89
388	NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017053.	1.3	18
389	Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4843-4858.	2.0	4
390	Solitary Bone Plasmacytoma of the Pelvis: A Rare Tumor. <i>Rare Tumors</i> , 2016, 8, 39-41.	0.6	2
391	Two Cases of Heavy Chain MGUS. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-4.	0.3	4
392	Imaging Findings of Plasmacytoma of Both Breasts as a Preceding Manifestation of Multiple Myeloma. <i>Case Reports in Medicine</i> , 2016, 2016, 1-5.	0.7	7
393	Plasma Levels of Monocyte Chemotactic Protein-1 Are Associated with Clinical Features and Angiogenesis in Patients with Multiple Myeloma. <i>BioMed Research International</i> , 2016, 2016, 1-7.	1.9	10
394	The Diagnosis and Treatment of Multiple Myeloma. <i>Deutsches A&#x0308;rztblatt International</i> , 2016, 113, 470-6.	0.9	129

#	ARTICLE	IF	CITATIONS
395	Non-secretory multiple myeloma: from biology to clinical management. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7583-7590.	2.0	39
396	Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study. <i>PLoS ONE</i> , 2016, 11, e0154993.	2.5	22
397	Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma. <i>Medicine (United States)</i> , 2016, 95, e3521.	1.0	24
398	Abdominal adipose tissue in MGUS and multiple myeloma. <i>Skeletal Radiology</i> , 2016, 45, 1277-1283.	2.0	24
399	Quadruple Cancers of Non-producing Multiple Myeloma, Cholangiocellular Carcinoma, and Two Different Thyroid Cancers. <i>Internal Medicine</i> , 2016, 55, 1183-1186.	0.7	1
400	Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head. <i>Journal of International Medical Research</i> , 2016, 44, 1462-1473.	1.0	5
401	Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma. <i>Cancer Medicine</i> , 2016, 5, 3051-3058.	2.8	3
402	Monoclonal gammopathy of undetermined significance and endoneurial IgG deposition. <i>Medicine (United States)</i> , 2016, 95, e4807.	1.0	10
403	Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. <i>Haematologica</i> , 2016, 101, 356-362.	3.5	25
404	Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. <i>Leukemia</i> , 2016, 30, 2026-2031.	7.2	19
405	Presentation of multiple myeloma mimicking bone metastasis from colon adenocarcinoma: A case report and literature review. <i>Molecular and Clinical Oncology</i> , 2016, 4, 31-34.	1.0	4
406	The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution. <i>Cancer Medicine</i> , 2016, 5, 500-505.	2.8	5
407	A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis. <i>British Journal of Haematology</i> , 2016, 174, 748-759.	2.5	48
409	Current Trends of Renal Impairment in Multiple Myeloma. <i>Kidney Diseases (Basel, Switzerland)</i> , 2015, 1, 241-257.	2.5	66
410	Multiple myeloma epidemiology and survival: A unique malignancy. <i>Seminars in Oncology</i> , 2016, 43, 676-681.	2.2	492
411	Plasma Cell Leukemia Presenting as a Chest Wall Mass: A Case Report. <i>Case Reports in Oncology</i> , 2016, 9, 338-343.	0.7	4
412	Labordiagnostik bei der monoklonalen Gammopathie unklarer Signifikanz (MGUS). <i>Laboratoriums Medizin</i> , 2016, 40, .	0.6	0
413	Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLapsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. <i>BMC Cancer</i> , 2016, 16, 290.	2.6	5

#	ARTICLE	IF	CITATIONS
414	Cutaneous plasmacytoma adjacent to Bowenoid actinic keratosis on the scalp: Is there a link?. International Journal of Surgery Case Reports, 2016, 21, 52-54.	0.6	3
415	When an Analytical Interference Is a Useful Diagnostic Tool: Finding Monoclonal Gammopathies in Routine Analysis. Journal of Clinical Laboratory Analysis, 2016, 30, 140-144.	2.1	6
416	Oligodendroglioma metastasis to the bone marrow mimicking multiple myeloma: A case report. Oncology Letters, 2016, 12, 351-355.	1.8	3
417	Clinical characteristics and outcomes in biclonal gammopathies. American Journal of Hematology, 2016, 91, 473-475.	4.1	30
418	Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease. Journal of Oncology Pharmacy Practice, 2016, 22, 289-302.	0.9	21
419	Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cellular and Molecular Life Sciences, 2016, 73, 1569-1589.	5.4	100
420	Is accuracy of serum free light chain measurement achievable?. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1021-30.	2.3	38
421	Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. Journal of Proteomics, 2016, 136, 89-98.	2.4	68
422	A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. International Journal of Hematology, 2016, 103, 25-33.	1.6	14
423	Vertebral lesion distribution in multiple myeloma assessed by reduced-dose whole-body MDCT. Skeletal Radiology, 2016, 45, 127-133.	2.0	9
424	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Oncologist, 2016, 21, 333-342.	3.7	28
425	High prevalence of secondary factors for bone fragility in patients with a recent fracture independently of BMD. Archives of Osteoporosis, 2016, 11, 12.	2.4	30
426	Paraproteinemic neuropathy: a practical review. BMC Neurology, 2016, 16, 13.	1.8	54
427	Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China. Tumor Biology, 2016, 37, 7893-7900.	1.8	10
428	Hematolymphoid lesions of the sinonasal tract. Seminars in Diagnostic Pathology, 2016, 33, 71-80.	1.5	17
429	Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study. Journal of the National Cancer Institute, 2017, 109, djw264.	6.3	61
430	Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma. Blood Cancer Journal, 2017, 7, e530-e530.	6.2	33
431	Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma. BMC Infectious Diseases, 2017, 17, 33.	2.9	24

#	ARTICLE	IF	CITATIONS
432	The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 771-778.	1.9	5
433	End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma. <i>Future Oncology</i> , 2017, 13, 1181-1193.	2.4	25
434	Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. <i>Haematologica</i> , 2017, 102, 1099-1104.	3.5	81
435	Identification and expression of MMSA-8, and its clinical significance in multiple myeloma. <i>Oncology Reports</i> , 2017, 37, 3235-3243.	2.6	2
436	Prevalence of Monoclonal Gammopathy of Undetermined Significance in an Apparently Healthy Yixing Population in Mainland China. <i>Acta Haematologica</i> , 2017, 137, 17-19.	1.4	1
437	Improved MDCT monitoring of pelvic myeloma bone disease through the use of a novel longitudinal bone subtraction post-processing algorithm. <i>European Radiology</i> , 2017, 27, 2969-2977.	4.5	4
438	Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation. <i>Annals of Oncology</i> , 2017, 28, 2503-2510.	1.2	45
439	Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. <i>Blood Cancer Journal</i> , 2017, 7, e599-e599.	6.2	124
440	Pleural Effusion in Multiple Myeloma: Characteristics and Practice Patterns. <i>Acta Haematologica</i> , 2017, 138, 69-76.	1.4	16
441	Long-term Clinical Outcome of Antibody Replacement Therapy in Humoral Immunodeficient Adults With Respiratory Tract Infections. <i>EBioMedicine</i> , 2017, 18, 254-260.	6.1	9
442	Pseudo-monoclonal gammopathy: a report of four cases. <i>Haematologica</i> , 2017, 102, e466-e469.	3.5	11
443	Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma. <i>Medicine (United States)</i> , 2017, 96, e5787.	1.0	8
444	Extra-skeletal plasmablastic myeloma presenting as palatal growth “An unusual entity. <i>International Journal of Surgery Case Reports</i> , 2017, 41, 423-426.	0.6	4
445	Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry. <i>Clinics in Laboratory Medicine</i> , 2017, 37, 821-853.	1.4	20
446	Expressed fusion gene landscape and its impact in multiple myeloma. <i>Nature Communications</i> , 2017, 8, 1893.	12.8	31
447	The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study. <i>Cancer Medicine</i> , 2017, 6, 1807-1816.	2.8	39
448	Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 742-749.	2.0	37
449	Extramedullary plasmacytoma of the ureter in an HIV-positive patient. <i>International Cancer Conference Journal</i> , 2017, 6, 171-174.	0.5	2

#	ARTICLE	IF	CITATIONS
450	IgMk paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: a case report. BMC Immunology, 2017, 18, 32.	2.2	9
451	Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report. BMC Nephrology, 2017, 18, 127.	1.8	14
452	Vectored immunoprophylaxis: an emerging adjunct to traditional vaccination. Tropical Diseases, Travel Medicine and Vaccines, 2017, 3, 3.	2.2	23
453	Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clinical Cancer Research, 2017, 23, 2665-2672.	7.0	13
454	The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma. Leukemia, 2017, 31, 853-860.	7.2	72
455	Observational study of multiple myeloma in Latin America. Annals of Hematology, 2017, 96, 65-72.	1.8	29
456	Comparison of Fully Automated and Semiautomated Systems for Protein Immunofixation Electrophoresis. Journal of Clinical Laboratory Analysis, 2017, 31, e22027.	2.1	3
457	The Predictive Role of the Neutrophil/Lymphocyte Ratio in Survival with Multiple Myeloma: A Single Center Experience. Journal of Clinical Laboratory Analysis, 2017, 31, e22032.	2.1	15
458	Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 50-62.	6.4	37
459	Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Leukemia and Lymphoma, 2017, 58, 639-645.	1.3	11
460	Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia, 2017, 31, 130-135.	7.2	63
461	Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. Leukemia, 2017, 31, 136-142.	7.2	50
462	A Study on Free Light Chain Assay and Serum Immunofixation Electrophoresis for the Diagnosis of Monoclonal Gammopathies. Indian Journal of Clinical Biochemistry, 2019, 34, 76-81.	1.9	0
464	The Coexistence of Multiple Myeloma-associated Amyloid Light-chain Amyloidosis and Fabry Disease in a Hemodialysis Patient. Internal Medicine, 2017, 56, 841-846.	0.7	6
465	AKI in Multiple Myeloma: Paraproteins, Metabolic Disturbances, and Drug Toxicity. Journal of Onco-Nephrology, 2017, 1, 188-197.	0.6	5
466	An uncommon hip pain. BMJ Case Reports, 2017, 2017, bcr-2017-221717.	0.5	0
467	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Advances, 2017, 1, 1911-1918.	5.2	37
468	Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. Blood Advances, 2017, 1, 2186-2192.	5.2	47

#	ARTICLE	IF	CITATIONS
469	Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Oncology Letters</i> , 2017, 14, 4372-4378.	1.8	9
470	Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases. <i>International Journal of Molecular Sciences</i> , 2017, 18, 804.	4.1	7
471	Solitary Plasmacytoma of the Mesentery: A Systematic Clinician's Diagnosis. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-4.	0.3	4
472	Diagnostic utility of whole body Dixon MRI in multiple myeloma: A multi-reader study. <i>PLoS ONE</i> , 2017, 12, e0180562.	2.5	38
473	High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma. <i>PLoS ONE</i> , 2017, 12, e0181487.	2.5	10
474	Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population. <i>PLoS ONE</i> , 2017, 12, e0188988.	2.5	36
475	N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma. <i>BMC Cancer</i> , 2017, 17, 881.	2.6	14
476	Strategy for the treatment and follow-up of sinonasal solitary extramedullary plasmacytoma: a case series. <i>Journal of Medical Case Reports</i> , 2017, 11, 219.	0.8	19
477	Characteristics and Prognosis of Patients with Immunoglobulin M Monoclonal Gammopathy. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2017, 57, 47-53.	0.8	3
478	Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis in 55 patients. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017, 29, 438-446.	2.2	22
479	Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions. <i>Cancer Management and Research</i> , 2017, Volume 9, 189-196.	1.9	13
481	Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era. <i>Hematology Reports</i> , 2017, 9, 16-18.	0.8	20
482	Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-8.	2.1	12
483	Panoramic and skull imaging may aid in the identification of multiple myeloma lesions. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2017, 23, 0-0.	1.7	5
484	Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma. <i>Cancer Science</i> , 2018, 109, 1552-1561.	3.9	10
485	Short overview on the current standard of treatment in newly diagnosed multiple myeloma. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 59-64.	0.5	8
486	The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. <i>Acta Pharmaceutica Sinica B</i> , 2018, 8, 539-551.	12.0	141
487	Stem cell mobilization kinetics in elderly patients with multiple myeloma. <i>Transfusion and Apheresis Science</i> , 2018, 57, 204-207.	1.0	0

#	ARTICLE	IF	CITATIONS
488	Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 219-224.	0.4	34
489	Comparison of qualitative and quantitative CT and MRI parameters for monitoring of longitudinal spine involvement in patients with multiple myeloma. <i>Skeletal Radiology</i> , 2018, 47, 351-361.	2.0	10
490	A rare case of a minimally secretory plasma cell leukemia with a hemorrhagic gastric plasmacytoma. <i>Leukemia Research Reports</i> , 2018, 9, 23-27.	0.4	0
491	Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. <i>Blood Cancer Journal</i> , 2018, 8, 31.	6.2	35
492	Monoclonal gammopathy in rheumatic diseases. <i>Clinical Rheumatology</i> , 2018, 37, 1751-1762.	2.2	22
493	Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 178-186.	1.3	2
494	Natural history of t(11;14) multiple myeloma. <i>Leukemia</i> , 2018, 32, 131-138.	7.2	67
495	Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines. <i>European Radiology</i> , 2018, 28, 683-691.	4.5	33
496	Epigenetic silencing of LPP/miR-28 in multiple myeloma. <i>Journal of Clinical Pathology</i> , 2018, 71, 253-258.	2.0	15
497	Serum free light chain-only multiple myeloma associated with multiple bone involvement and the t(11;14)(q13;q32)/<i>CCND1</i>/<i>immunoglobulin heavy chain fusion gene: A report of three cases . <i>Tenri Medical Bulletin</i> , 2018, 21, 56-69.	0.1	0
498	Cutaneous comorbidities in patients with multiple myeloma. <i>Medicine (United States)</i> , 2018, 97, e12825.	1.0	2
499	Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPIn® protein MP0250: a preclinical study. <i>Oncotarget</i> , 2018, 9, 13366-13381.	1.8	37
500	Lingual liability: macroglossia and dyspnoea as the harbinger of systemic AL (light-chain) cardiac amyloidosis. <i>BMJ Case Reports</i> , 2018, 11, e225923.	0.5	2
501	CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 2722.	4.8	124
502	Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. <i>Blood Cancer Journal</i> , 2018, 8, 95.	6.2	59
503	Biliary Obstruction due to a Pancreatic Plasmacytoma. <i>Case Reports in Gastrointestinal Medicine</i> , 2018, 2018, 1-3.	0.3	2
504	Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies. <i>Journal of Neurology</i> , 2018, 265, 2927-2933.	3.6	12
505	Dietary intake is associated with risk of multiple myeloma and its precursor disease. <i>PLoS ONE</i> , 2018, 13, e0206047.	2.5	19

#	ARTICLE	IF	CITATIONS
506	Association of CD117 and HLA-DR expression with shorter overall survival and/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation. <i>Oncology Letters</i> , 2018, 16, 5655-5666.	1.8	7
507	The Genetic Polymorphisms of NLRP3 Inflammasome Associated with T Helper Cells in Patients with Multiple Myeloma. <i>Journal of Immunology Research</i> , 2018, 2018, 1-13.	2.2	18
508	Applications of PET/CT and PET/MR Imaging in Primary Bone Malignancies. <i>PET Clinics</i> , 2018, 13, 623-634.	3.0	47
509	Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction study. <i>Molecular Medicine</i> , 2018, 24, 30.	4.4	9
510	Clinical significance of cancer-related fatigue in multiple myeloma patients. <i>International Journal of Hematology</i> , 2018, 108, 580-587.	1.6	9
511	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. <i>British Journal of Haematology</i> , 2018, 182, 495-503.	2.5	30
512	Recurrence of paraproteinemic keratopathy after penetrating keratoplasty and its assessment with confocal microscopy. <i>American Journal of Ophthalmology Case Reports</i> , 2018, 11, 87-91.	0.7	8
513	Impact of hemodialysis on the prognosis of multiple myeloma: A nationwide population-based study and single-institute analysis. <i>Oncology Letters</i> , 2018, 16, 1991-2002.	1.8	3
514	Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma. <i>Annals of Laboratory Medicine</i> , 2018, 38, 160-164.	2.5	1
515	Multiple Myeloma Index for Risk of Infection. <i>Journal of Cancer</i> , 2018, 9, 2211-2214.	2.5	14
516	Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma. <i>BMC Cancer</i> , 2018, 18, 650.	2.6	4
517	Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma. <i>Leukemia Research</i> , 2018, 71, 106-111.	0.8	33
518	Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion. <i>Internal Medicine</i> , 2018, 57, 855-860.	0.7	1
519	Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells. <i>Cell Death and Disease</i> , 2018, 9, 512.	6.3	25
520	The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. <i>PLoS ONE</i> , 2018, 13, e0202045.	2.5	40
521	Abnormal Plasma Cell Disorders in Refinery Waste Workers. <i>Journal of Clinical Medicine</i> , 2018, 7, 221.	2.4	4
522	A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma. <i>Experimental Hematology and Oncology</i> , 2018, 7, 18.	5.0	9
523	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018, 8, 59.	6.2	171

#	ARTICLE	IF	CITATIONS
524	Solitary Plasmacytoma of Frontal Bone: A Case Report. Indian Journal of Otolaryngology and Head and Neck Surgery, 2019, 71, 1944-1947.	0.9	2
525	Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation. International Journal of Hematology, 2019, 110, 447-457.	1.6	1
526	Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 1760-1772.	10.7	109
527	Liquid Biopsies in Multiple Myeloma. , 0, , .		0
528	Multiple myeloma of young adult presented with paraplegia, rare case report in Saudi Arabia. BJR case Reports, 2019, 5, 20190008.	0.2	0
529	Monoclonal immunoglobulin-mediated kidney disease: What is beyond amyloidosis in real practice?. Journal of Onco-Nephrology, 2019, 3, 105-112.	0.6	1
530	Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study). International Journal of Hematology, 2019, 109, 409-417.	1.6	3
531	Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature. Journal of Medical Case Reports, 2019, 13, 153.	0.8	9
532	Low knowledge and awareness of monoclonal gammopathy of undetermined significance (MGUS) among general practitioners. BMC Family Practice, 2019, 20, 61.	2.9	4
533	Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer, 2019, 19, 504.	2.6	25
534	Presentation and survival of multiple myeloma patients in Ghana: a review of 9 cases. Ghana Medical Journal, 2019, 53, 52.	0.4	17
535	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2019, 54, 2039-2050.	2.4	9
536	Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact. Clinical Epigenetics, 2019, 11, 71.	4.1	23
537	Correlation Between Uptake of 18F-FDG During PET/CT and Ki-67 Expression in Patients Newly Diagnosed With Multiple Myeloma Having Extramedullary Involvement. Technology in Cancer Research and Treatment, 2019, 18, 153303381984906.	1.9	4
538	Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1397-1405.	2.3	7
539	Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease. Health Science Reports, 2019, 2, e113.	1.5	10
540	Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. Blood Cancer Journal, 2019, 9, 36.	6.2	11
541	Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?. Disease Markers, 2019, 2019, 1-6.	1.3	4

#	ARTICLE	IF	CITATIONS
542	Differential diagnosis between bone relapse of breast cancer and lambda light chain multiple myeloma: role of the clinical biochemist. Tumori, 2019, 105, NP17-NP19.	1.1	2
543	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	6.2	38
544	Survival rate of multiple myeloma patients in Indonesia: A retrospective study in multiple myeloma at a single institution. Annals of Medicine and Surgery, 2019, 41, 11-15.	1.1	6
545	Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples. Haematologica, 2019, 104, 2456-2464.	3.5	9
546	Health-Related Quality of Life and Satisfaction With Health Care: Relation to Clinical Stage in Mexican Patients With Multiple Myeloma. Cancer Control, 2019, 26, 107327481983128.	1.8	1
547	Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial. Acta Haematologica, 2019, 141, 111-118.	1.4	4
548	Lymphomas of the head and neck region: an update. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 649-665.	2.8	24
549	Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 2055-2061.	2.5	6
550	Primary plasmablastic plasmacytoma in the stomach of an immunocompetent adult. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10	1.0	7
551	Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background. Blood Cancer Journal, 2019, 9, 90.	6.2	16
552	Bone marrow endothelial cells sustain a tumor-specific CD8 ⁺ T cell subset with suppressive function in myeloma patients. Oncoimmunology, 2019, 8, e1486949.	4.6	58
553	Proposal of new clinical diagnostic criteria for POEMS syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 133-137.	1.9	21
554	Pseudo-monoclonal gammopathy due to autoimmune disease: a case report. Journal of International Medical Research, 2020, 48, 030006051986661.	1.0	0
555	Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation. Hematology, Transfusion and Cell Therapy, 2020, 42, 118-124.	0.2	2
556	Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 284-291.	0.6	2
557	Prognostic factor of poor outcome in anti-MAG neuropathy: clinical and electrophysiological analysis of a French Cohort. Journal of Neurology, 2020, 267, 561-571.	3.6	7
558	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American Journal of Hematology, 2020, 95, 4-9.	4.1	14
559	Clinical Features of Head and Neck Solitary Extramedullary Plasmacytoma in Taiwan. In Vivo, 2020, 34, 261-265.	1.3	7

#	ARTICLE	IF	CITATIONS
560	Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 749-759.	2.5	9
561	Extramedullary multiple myeloma. <i>Leukemia</i> , 2020, 34, 1-20.	7.2	140
562	CCN1 stimulated the osteoblasts via PTEN/AKT/GSK3 β /cyclinD1 signal pathway in Myeloma Bone Disease. <i>Cancer Medicine</i> , 2020, 9, 737-744.	2.8	11
563	Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma. <i>Cancers</i> , 2020, 12, 12.	3.7	25
564	Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics. <i>BMC Infectious Diseases</i> , 2020, 20, 699.	2.9	15
565	Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies. <i>BioMed Research International</i> , 2020, 2020, 1-9.	1.9	9
566	Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). <i>Leukemia</i> , 2020, 34, 3111-3125.	7.2	39
567	What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?. <i>Frontiers in Oncology</i> , 2020, 10, 538126.	2.8	10
568	Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23416.	2.1	9
569	Multiple Myeloma Associated Bone Disease. <i>Cancers</i> , 2020, 12, 2113.	3.7	35
570	Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China. <i>Cancer Medicine</i> , 2020, 9, 7819-7829.	2.8	8
571	Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination. <i>Cancer Cell International</i> , 2020, 20, 403.	4.1	11
572	Extramedullary nasal plasmacytoma arising after polyp excision and the role of the inflammation in tumor development: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 12, 451-455.	1.0	4
573	Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria. <i>Cancers</i> , 2020, 12, 2537.	3.7	7
574	The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis. <i>Cancers</i> , 2020, 12, 2341.	3.7	4
575	A challenging diagnosis of a nonsecretor plasma cell dyscrasia with pleomorphic plasmablastic morphology. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3069-3073.	0.5	0
576	Impact of Extended Treatment Interval on the Prognosis of Multiple Myeloma Patients: A Retrospective Study. <i>Oncology Research and Treatment</i> , 2020, 43, 592-604.	1.2	1
577	DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma. <i>Clinical Epigenetics</i> , 2020, 12, 163.	4.1	9

#	ARTICLE	IF	CITATIONS
578	Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?. <i>Cancers</i> , 2020, 12, 1223.	3.7	9
579	Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma. <i>Journal of Cancer</i> , 2020, 11, 1182-1194.	2.5	24
580	Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance. <i>Bone</i> , 2020, 137, 115394.	2.9	5
581	Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?. <i>Cancers</i> , 2020, 12, 1335.	3.7	6
582	Detection of Circulating Tumor Plasma Cells in Monoclonal Gammopathies: Methods, Pathogenic Role, and Clinical Implications. <i>Cancers</i> , 2020, 12, 1499.	3.7	19
583	Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 4688-4698.	7.0	30
584	Septal Nasal Extramedullary Plasmacytoma: A Rare Tumor in an Unusual Area. <i>Ear, Nose and Throat Journal</i> , 2021, 100, 805S-807S.	0.8	2
585	Rotating Nightshift Work and Hematopoietic Cancer Risk in US Female Nurses. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz106.	2.9	5
586	Mathematical modelling of the role of GADD45 ¹² in the pathogenesis of multiple myeloma. <i>Royal Society Open Science</i> , 2020, 7, 192152.	2.4	1
587	Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23233.	2.1	15
588	Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 552.	2.4	40
589	High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101152.	1.7	9
590	HB-EGFâ€“EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma. <i>Cancers</i> , 2020, 12, 173.	3.7	28
591	Monoclonal Gammopathies After Renal Transplantation: A Single-center Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e468-e473.	0.4	4
592	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 596-601.	0.4	15
593	Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105). <i>British Journal of Haematology</i> , 2021, 192, 531-541.	2.5	9
594	Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A populationâ€“based study. <i>Cancer Medicine</i> , 2021, 10, 462-470.	2.8	11
595	Impact of CD138 Magnetic Bead-based Positive Selection on Bone Marrow Plasma Cell Surface Markers. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e48-e51.	0.4	1

#	ARTICLE	IF	CITATIONS
596	What Is New in the Treatment of Smoldering Multiple Myeloma?. Journal of Clinical Medicine, 2021, 10, 421.	2.4	7
597	Solitary plasmacytoma of mandible: an unusual bilateral presentation. Autopsy and Case Reports, 2021, 11, e2021298.	0.6	1
598	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature Communications, 2021, 12, 293.	12.8	54
599	A Case of Extraosseous Plasmacytoma that Developed in the Sinonasal Cavity. Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology), 2021, 60, 13-20.	0.0	0
600	Potential effect of epigenetic drugs in the treatment of multiple-site extramedullary plasmacytoma involving the respiratory system: a case report and review of the literature. Translational Cancer Research, 2021, 10, 4262-4273.	1.0	1
601	A case of solitary plasmacytoma in the mandible. Journal of Japanese Society of Oral Oncology, 2021, 33, 143-149.	0.1	0
602	Does chemical shift imaging offer a biomarker for the diagnosis and assessment of disease severity in multiple myeloma?. Medicine (United States), 2021, 100, e24358.	1.0	3
603	The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. Cancers, 2021, 13, 951.	3.7	9
604	Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells, 2021, 10, 336.	4.1	48
605	Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. Cancers, 2021, 13, 961.	3.7	8
606	An unusual pattern in serum protein electrophoresis to take in mind: A case report. Practical Laboratory Medicine, 2021, 24, e00200.	1.3	3
607	Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma. Blood Advances, 2021, 5, 1746-1754.	5.2	10
608	Prognostic value of the albuminâ€globulin ratio and albuminâ€globulin score in patients with multiple myeloma. Journal of International Medical Research, 2021, 49, 030006052199773.	1.0	10
609	Crystalline deposits in the cornea and various areas of the kidney as symptoms of an underlying monoclonal gammopathy: a case report. BMC Nephrology, 2021, 22, 117.	1.8	2
610	Kidney Biopsy in Patients With Monoclonal Gammopathy: A Multicenter Retrospective Cohort Study. Frontiers in Medicine, 2021, 8, 687149.	2.6	4
611	A Rare Case of Small Bowel Extramedullary Plasmacytomas Presenting With Intestinal Obstruction. Cureus, 2021, 13, e15704.	0.5	2
612	Ocular Signs and Ocular Comorbidities in Monoclonal Gammopathy: Analysis of 80 Subjects. Journal of Ophthalmology, 2021, 2021, 1-8.	1.3	3
613	Detection of monoclonal protein by capillary zone electrophoresis can be challenged by iodinated contrast agent interference: a case report. Biochemia Medica, 2021, 31, 359-362.	2.7	2

#	ARTICLE	IF	CITATIONS
614	Possible Therapeutic Potential of Disulfiram for Multiple Myeloma. <i>Current Oncology</i> , 2021, 28, 2087-2096.	2.2	1
615	Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2664-2671.	2.4	9
616	Monoclonal gammopathy of undetermined significance. <i>InnovAiT</i> , 0, , 175573802110279.	0.0	0
617	Oncologist perspective: role of imaging in myeloma. <i>Skeletal Radiology</i> , 2022, 51, 123-133.	2.0	1
618	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.	3.5	22
619	Immune subtraction for improved resolution in serum protein immunofixation electrophoresis and antibody isotype determination in a patient with autoantibody. <i>Practical Laboratory Medicine</i> , 2021, 26, e00240.	1.3	0
620	To Treat or Not to Treat: A Case of Simultaneous Discovery of Chronic Myelomonocytic Leukemia and Multiple Myeloma. <i>Cureus</i> , 2021, 13, e17505.	0.5	0
621	Multiple myeloma in Armenia during the period 2006â€“2018: facts and discussion. <i>BMC Cancer</i> , 2021, 21, 941.	2.6	4
622	Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. <i>Annals of Hematology</i> , 2021, 100, 2997-3005.	1.8	2
623	Root Bark of <i>Morus alba</i> L. and Its Bioactive Ingredient, Ursolic Acid, Suppress the Proliferation of Multiple Myeloma Cells by Inhibiting Wnt/ β -Catenin Pathway. <i>Journal of Microbiology and Biotechnology</i> , 2021, 31, 1559-1567.	2.1	6
624	LBX2-AS1 as a Novel Diagnostic Biomarker and Therapeutic Target Facilitates Multiple Myeloma Progression by Enhancing mRNA Stability of LBX2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 706570.	3.5	3
625	Podocytopathy in patients with monoclonal gammopathy: three patients and literature review. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 417-424.	2.9	3
626	Extramedullary plasmacytoma of the ureter. <i>IJU Case Reports</i> , 2022, 5, 19-22.	0.3	2
627	Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study. <i>Scientific Reports</i> , 2021, 11, 19266.	3.3	2
628	Association between Kidney Function, Proteinuria and the Risk of Multiple Myeloma: A Population-Based Retrospective Cohort Study in South Korea. <i>Cancer Research and Treatment</i> , 2022, 54, 926-936.	3.0	2
629	Artefactual bands on urine protein immunofixation gels. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e283-e284.	2.3	0
630	Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100444.	1.7	5
631	Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2099.	7.4	120

#	ARTICLE	IF	CITATIONS
632	Amyloidosis: an unusual cause of upper gastrointestinal bleeding. BMJ Case Reports, 2016, 2016, bcr2016217653.	0.5	11
633	Orbital multiple myeloma: a diagnostic challenge. BMJ Case Reports, 2017, 2017, bcr-2017-220895.	0.5	8
634	Testicular plasmacytoma misdiagnosed as orchitis. BMJ Case Reports, 2018, 2018, bcr-2017-222046.	0.5	2
635	Incidence and Risk Factors of Osteonecrosis of Femoral Head in Multiple Myeloma Patients Undergoing Dexamethasone-Based Regimens. BioMed Research International, 2020, 2020, 1-7.	1.9	4
636	Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma. Acta Haematologica, 2021, 144, 264-274.	1.4	2
637	A case of IgE myeloma transformed into IgE-producing plasma cell leukaemia. Biochemia Medica, 2020, 30, 134-142.	2.7	5
638	The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. Singapore Medical Journal, 2017, 58, 55-71.	0.6	6
639	Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma. JCI Insight, 2019, 4, .	5.0	18
640	Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy. Journal of Clinical Investigation, 2016, 126, 1300-1310.	8.2	9
641	Advances in the understanding of IgM monoclonal gammopathy of undetermined significance. F1000Research, 2017, 6, 2142.	1.6	11
642	Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors. PLoS ONE, 2013, 8, e83905.	2.5	16
643	Magnetic Resonance Evaluation of Multiple Myeloma at 3.0 Tesla: How Do Bone Marrow Plasma Cell Percentage and Selection of Protocols Affect Lesion Conspicuity?. PLoS ONE, 2014, 9, e85931.	2.5	4
644	Iterative Decomposition of Water and Fat with Echo Asymmetry and Least-Squares Estimation (IDEAL) Magnetic Resonance Imaging as a Biomarker for Symptomatic Multiple Myeloma. PLoS ONE, 2015, 10, e0116842.	2.5	28
645	Whole body MRI in multiple myeloma: Optimising image acquisition and read times. PLoS ONE, 2020, 15, e0228424.	2.5	8
646	NF- κ B Activation in U266 Cells on Mesenchymal Stem Cells. Advanced Pharmaceutical Bulletin, 2016, 6, 415-422.	1.4	3
647	The solitary sellar plasmacytoma: a diagnostic challenge. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, 160031.	0.5	7
648	mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein. Oncoscience, 2015, 2, 382-394.	2.2	10
649	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. Oncotarget, 2016, 7, 59029-59048.	1.8	16

#	ARTICLE	IF	CITATIONS
650	Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. <i>Oncotarget</i> , 2017, 8, 84847-84862.	1.8	7
651	Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma. <i>Oncotarget</i> , 2017, 8, 69408-69421.	1.8	15
652	Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 18792-18801.	1.8	71
653	Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?. <i>Oncotarget</i> , 2017, 8, 5081-5091.	1.8	14
654	Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia. <i>Oncotarget</i> , 2017, 8, 19427-19442.	1.8	11
655	Association of VEGF and VDR gene- gene and gene- smoking interaction on risk of multiple myeloma in Chinese Han population. <i>Oncotarget</i> , 2017, 8, 36509-36516.	1.8	8
656	Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 56243-56254.	1.8	15
657	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). <i>Oncotarget</i> , 2017, 8, 79517-79526.	1.8	16
658	Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway. <i>Oncotarget</i> , 2017, 8, 55405-55421.	1.8	13
659	Multiple myeloma cell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. <i>Oncotarget</i> , 2014, 5, 5686-5699.	1.8	59
660	Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma. <i>Oncotarget</i> , 2018, 9, 20563-20577.	1.8	45
661	Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients. <i>Oncotarget</i> , 2018, 9, 25254-25264.	1.8	15
662	LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. <i>Oncotarget</i> , 2014, 5, 12950-12967.	1.8	52
663	Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma. <i>Oncotarget</i> , 2019, 10, 6781-6790.	1.8	2
664	Molecular spectrum of <i>BRAF</i> , <i>NRAS</i> and <i>KRAS</i> gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. <i>Oncotarget</i> , 2015, 6, 24205-24217.	1.8	65
665	Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma. <i>Oncotarget</i> , 2015, 6, 17958-17967.	1.8	13
666	A compendium of <i>DIS3</i> mutations and associated transcriptional signatures in plasma cell dyscrasias. <i>Oncotarget</i> , 2015, 6, 26129-26141.	1.8	40
667	Notch signaling deregulation in multiple myeloma: A rational molecular target. <i>Oncotarget</i> , 2015, 6, 26826-26840.	1.8	47

#	ARTICLE	IF	CITATIONS
668	Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis. <i>Oncotarget</i> , 2016, 7, 19589-19600.	1.8	45
669	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. <i>Core Evidence</i> , 2010, 4, 215.	4.7	18
670	Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin's Lymphoma Patients. <i>Cell Journal</i> , 2017, 19, 44-54.	0.2	18
672	Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions. <i>Radiation Oncology Journal</i> , 2016, 34, 59-63.	1.5	17
673	The role of CT in PET/CT for assessing diffuse infiltration of bone marrow in multiple myeloma using the Durie-Salmon PLUS staging system. <i>Molecular and Clinical Oncology</i> , 2020, 13, 13-18.	1.0	3
674	Association between left ventricular function and paraprotein type in patients with multiple myeloma. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 459-468.	1.7	5
675	Recent advances in multiple myeloma: a Korean perspective. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 820-834.	1.7	22
676	Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 809-819.	1.7	8
677	Multiple solitary extramedullary anaplastic plasmacytomas. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2016, 37, 303-304.	0.2	4
678	Plasmacytoma of the testis in a patient with relapsed and refractory multiple myeloma: Case report and review of the literature. <i>Urology Annals</i> , 2015, 7, 530.	0.6	9
679	Solitary dural plasmacytoma with parenchymal invasion. <i>Journal of Innovative Optical Health Sciences</i> , 2015, 10, 102-104.	1.0	14
680	Gastrointestinal bleeding as initial presentation of extramedullary plasma cell neoplasms: A case report and review of the literature. <i>World Journal of Gastrointestinal Endoscopy</i> , 2019, 11, 308-321.	1.2	9
681	Solitary Plasmacytoma of the Sternum. <i>Korean Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 46, 482-485.	0.6	5
682	Refractory ascites as a presenting feature of extramedullary plasmacytoma in an end-stage renal disease patient with HIV infection. <i>Clinical Nephrology Case Studies</i> , 2019, 7, 7-10.	0.7	2
683	Oncohematological diseases in the Vale do Paraíba, State of São Paulo. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 33, 120-125.	0.7	4
684	Extramedullary Plasmacytoma of the Nasal Cavity Report of Three Cases With Review of the Literature. <i>Iranian Red Crescent Medical Journal</i> , 2013, 15, 363-6.	0.5	27
685	Multiple Myeloma, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1398-1435.	4.9	55
686	NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1154-1165.	4.9	113

#	ARTICLE	IF	CITATIONS
687	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1685-1717.	4.9	138
689	Clarifying the molecular mechanism of tomentosinâ€induced antiproliferative and proapoptotic effects in human multiple myeloma via gene expression profile and genetic interaction network analysis. International Journal of Molecular Medicine, 2021, 48, .	4.0	2
690	The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Research, 2021, 11, 100.	2.5	12
691	Ixazomibâ€based maintenance therapy after bortezomibâ€based induction in patients with multiple myeloma not undergoing transplantation: A realâ€world study. Cancer Medicine, 2021, , .	2.8	7
692	Monoclonal Gammopathy of Undetermined Significance Disguised as Chronic Neutrophilic Leukemia. Mediterranean Journal of Hematology and Infectious Diseases, 2010, 2, e2010002.	1.3	4
693	Surgical resection of solitary plasmacytoma growing rapidly in the chest wall. The Journal of the Japanese Association for Chest Surgery, 2010, 24, 1032-1036.	0.0	1
694	Detection of Skeletal Lesions by Whole Body Multidetector Computed Tomography in Multiple Myeloma has no Impact on Long-Term Outcomes Post Autologous Hematopoietic Cell Transplantation. World Journal of Oncology, 2012, 3, 147-157.	1.5	3
695	A resected case of solitary plasmacytoma of the rib. The Journal of the Japanese Association for Chest Surgery, 2012, 26, 085-089.	0.0	0
696	Extramedullary Plasmacytoma of the Lung â€ Rather a Disseminated than a Localized Disease? â€ A Case Report of a Primary Pulmonary Plasmacytoma Showing Distinct Signs of Systemic Spread. Journal of Cancer Research Updates, 0, , .	0.3	0
697	A case of metachronous multiple plasmacytoma involving the mandible. Nihon Koku Geka Gakkai Zasshi, 2012, 58, 302-306.	0.0	2
698	Tratamiento de primera l�nea para pacientes con mieloma m�ltiple no elegibles para trasplante aut�logo de c�lulas progenitoras : revisi�n sistem�tica y meta-an�lisis (estudio del Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 337 Td (0.0	0
699	A Case of Primary Lung Cancer with Synchronous Costal Plasmacytoma. Japanese Journal of Lung Cancer, 2013, 53, 47-51.	0.1	1
700	Case 3/2014 - 81-Year-Old Patient Hospitalized for Decompensated Heart Failure. Arquivos Brasileiros De Cardiologia, 2014, 103, e1-e10.	0.8	0
701	Pancytopenia in Multiple Myeloma- An Enigma: Our Experience from Tertiary Care Hospital. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, EC04-6.	0.8	5
702	II. The Diagnosis of Multiple Myeloma. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1209-1215.	0.0	0
703	Non-Secretory Myeloma, Diagnosed on Renal Biopsy as Cast Nephropathy. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, ED04-5.	0.8	0
704	A Case of Pulmonary Plasmacytoma with Amyloid Deposition. Nihon Rinsho Geka Gakkai Zasshi (Journal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 337 Td (0.0	1
705	Warfarin improves neuropathy in monoclonal gammopathy of undetermined significance. BMJ Case Reports, 2016, 2016, bcr2016215518.	0.5	0

#	ARTICLE	IF	CITATIONS
706	A case of extramedullary plasmacytoma of the tongue. Nihon Koku Geka Gakkai Zasshi, 2017, 63, 374-377.	0.0	1
707	A case of multiple myeloma with bilateral hydronephrosis due to an extramedullary bladder lesion. Nihon Toseki Igakkai Zasshi, 2018, 51, 517-523.	0.1	0
708	âŠšè...žéâ´éâ´è...«ç~â´,â´ç™ç—†çŠřāā—āŸéžā^†æ³CEāž<âšç™æššéâ´é«„è...«ā@1/4´ā³4«. Orthopedics & Traumatology, 2018, 67, 185-188.	0.0	0
709	A Case of Extramedullary Plasmacytoma of the Sigmoid Colon. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2019, 80, 2250-2256.	0.0	0
710	A Case of Solitary Extramedullary Plasmacytoma of the Spleen. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2019, 80, 1234-1238.	0.0	0
711	Atraumatic Splenic Rupture in Uncomplicated Multiple Myelomaâ€”A Case Reportâ€”. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2019, 80, 995-1000.	0.0	0
712	A case of solitary plasmacytoma in the mandible transformed into multiple myeloma. Nihon Koku Geka Gakkai Zasshi, 2019, 65, 110-114.	0.0	1
713	Plasma cell leukemia - one in a million: A case report. World Journal of Clinical Oncology, 2019, 10, 161-165.	2.3	1
715	Significance of urinary albumin excretion inÂpatients with cast nephropathy. Clinical Nephrology, 2019, 92, 81-88.	0.7	0
716	A Patient of Multiple Myeloma with Absent M-spike on Serum Protein Electrophoresis and Elevated Serum-Free Light Chains: A Case Report and Literature Review. Cureus, 2019, 11, e5398.	0.5	1
718	Prevalence and prognostic value of monoclonal gammopathy in heart failure patients with preserved ejection fraction: A prospective study. Cardiology Journal, 2020, , .	1.2	1
719	Initial manifestation of parotid extraâ€medullary myeloma in an HIV positive patient on antiâ€retroviral therapy: A case report and review of the literature. Biomedical Reports, 2020, 13, 28.	2.0	0
720	Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. Journal of Clinical Medicine, 2021, 10, 5028.	2.4	1
721	Acupuncture Synergized With Bortezomib Improves Survival of Multiple Myeloma Mice via Decreasing Metabolic Ornithine. Frontiers in Oncology, 2021, 11, 779562.	2.8	3
722	Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1720-1729.	4.9	1
723	Downregulation of microRNAâ€25â€3p inhibits the proliferation and promotes the apoptosis of multiple myeloma cells via targeting the PTEN/PI3K/AKT signaling pathway. International Journal of Molecular Medicine, 2020, 47, .	4.0	14
724	Double-Hit Primary Plasma Cell Leukemia with IGH/MYC and IGH/CCND1 Translocations. Case Reports in Hematology, 2020, 2020, 1-5.	0.4	0
725	Identification of glutathione Sâ€transferase Î€ 1 as a prognostic proteomic biomarker for multiple myeloma using proteomic profiling. Oncology Letters, 2020, 19, 2153-2162.	1.8	1

#	ARTICLE	IF	CITATIONS
726	Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma. <i>Clinical Hematology International</i> , 2020, 2, 35.	1.7	0
727	Multiple myeloma with esophageal involvement: A rare case. <i>DEN Open</i> , 2022, 2, e71.	0.9	1
728	^{99m} Tc-sestamibi SPECT/CT and ¹⁸ F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma. <i>Nuclear Medicine Communications</i> , 2020, 41, 1081-1088.	1.1	9
729	Myeloma-Related Disorders in Cats Commonly Present as Extramedullary Neoplasms in Contrast to Myeloma in Human Patients: 24 Cases with Clinical Follow-up. <i>Journal of Veterinary Internal Medicine</i> , 2006, 20, 1376.	1.6	14
730	Immunoglobulin A multiple myeloma with cutaneous involvement in a dog. <i>Canadian Veterinary Journal</i> , 2008, 49, 694-702.	0.0	15
731	Screening panels for monoclonal gammopathies: time to change. <i>Clinical Biochemist Reviews</i> , 2009, 30, 105-11.	3.3	49
732	Reporting of quantitative protein electrophoresis in Australia and New Zealand: a call for standardisation. <i>Clinical Biochemist Reviews</i> , 2009, 30, 141-51.	3.3	7
733	Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. <i>Clinical Biochemist Reviews</i> , 2009, 30, 93-103.	3.3	18
734	Myeloma cells with asuophilic granules--an unusual morphological variant--case presentation. <i>Journal of Medicine and Life</i> , 2008, 1, 74-86.	1.3	6
735	Myelomatous Pleural Effusion: Case report and review of the literature. <i>Sultan Qaboos University Medical Journal</i> , 2011, 11, 259-64.	1.0	8
736	Bone marrow angiogenesis and progression in multiple myeloma. <i>American Journal of Blood Research</i> , 2011, 1, 76-89.	0.6	35
737	Biclonal light chain gammopathy with aberrant CD33 expression in secondary plasma cell leukemia. <i>International Journal of Clinical and Experimental Pathology</i> , 2013, 6, 2224-9.	0.5	6
738	Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). <i>Oncology</i> , 2011, 25, 578-86.	0.5	32
739	Discovering the meaning of monoclonal gammopathy of undetermined significance: current knowledge, future challenges. <i>Translational Medicine @ UniSa</i> , 2014, 8, 12-8.	0.5	4
740	A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 6313-22.	0.5	3
741	Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 469-78.	1.0	44
742	Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 479-92.	1.0	45
744	The Hematologic Definition of Monoclonal Gammopathy of Undetermined Significance in Relation to Paraproteinemic Keratopathy (An American Ophthalmological Society Thesis). <i>Transactions of the American Ophthalmological Society</i> , 2016, 114, T7.	1.4	15

#	ARTICLE	IF	CITATIONS
745	Quantitative analysis of F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 148-156.	1.0	7
746	Lithium chloride inhibits cell survival, overcomes drug resistance, and triggers apoptosis in multiple myeloma via activation of the Wnt/ β -catenin pathway. American Journal of Translational Research (discontinued), 2018, 10, 2610-2618.	0.0	8
747	Multiple Myeloma with Intracytoplasmic Azurophilic Granules. International Journal of Hematology-Oncology and Stem Cell Research, 2019, 13, 58-60.	0.3	0
748	Bone marrow PD-1 positive T cells reflect tumor mass and prognosis in multiple myeloma. International Journal of Clinical and Experimental Pathology, 2018, 11, 304-313.	0.5	7
756	Radiation response of soft-tissue extramedullary plasmacytoma in multiple myeloma—A case report. Clinical Case Reports (discontinued), 2021, 9, e05084.	0.5	1
757	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer Journal, 2021, 11, 186.	6.2	8
758	Prognostic Nomogram for Predicting Overall Survival of Solitary Bone Plasmacytoma Patients: A Large Population-Based Study. International Journal of General Medicine, 2021, Volume 14, 8621-8630.	1.8	2
759	Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma. European Radiology, 2021, , 1.	4.5	8
760	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal, 2021, 11, 192.	6.2	62
761	Solitary bone plasmacytoma as posterior fossa cranial neoplasia, presentation of two clinical cases. , 2022, 13, 7.		1
762	Plasma Cell Neoplasia. , 2020, , 283-297.		0
763	Metabolic Volume Measurements in Multiple Myeloma. Metabolites, 2021, 11, 875.	2.9	4
764	The Dynamics of Nucleotide Variants in the Progression from Low-Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach. Cancers, 2022, 14, 1035.	3.7	0
765	Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma. Cells, 2022, 11, 752.	4.1	4
766	Corneal Densitometry and In Vivo Confocal Microscopy in Patients with Monoclonal Gammopathy—Analysis of 130 Eyes of 65 Subjects. Journal of Clinical Medicine, 2022, 11, 1848.	2.4	4
767	Genomics of Plasma Cell Leukemia. Cancers, 2022, 14, 1594.	3.7	3
768	Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting. Frontiers in Oncology, 2022, 12, 830922.	2.8	12
769	Hidden in the Eyes—Recurrence of Systemic Hemopathies Reportedly “In Remission”: Six Cases and Review of Literature. Medicina (Lithuania), 2022, 58, 456.	2.0	2

#	ARTICLE	IF	CITATIONS
770	A genetic risk score of alleles related to MGUS interacts with socioeconomic position in a population-based cohort. Scientific Reports, 2022, 12, 4409.	3.3	0
771	Mesenchymal Stem Cells Inhibit the Effects of Dexamethasone in Multiple Myeloma Cells. Stem Cells International, 2022, 2022, 1-12.	2.5	3
772	Multi-trajectory models of serum biomarkers among patients with monoclonal gammopathy of undetermined significance. Hematological Oncology, 2022, 40, 409-416.	1.7	2
773	Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies. Hematology American Society of Hematology Education Program, 2021, 2021, 673-681.	2.5	7
774	Risk Stratification and Treatment in Smoldering Multiple Myeloma. Cells, 2022, 11, 130.	4.1	3
775	Echocardiography-defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients. Cancer Medicine, 2022, 11, 4182-4192.	2.8	3
783	The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value. Journal of Clinical Medicine, 2022, 11, 2513.	2.4	15
784	Extramedullary plasmacytoma: Tumor occurrence and therapeutic conceptsâ€”A follow-up. Cancer Medicine, 2022, 11, 4743-4755.	2.8	16
785	Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis. Skeletal Radiology, 2023, 52, 565-583.	2.0	5
786	Diagnostic Applications of Nuclear Medicine: Multiple Myeloma. , 2022, , 475-527.		0
787	Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma. Blood Cancer Journal, 2022, 12, .	6.2	1
789	Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment. GeroScience, 2023, 45, 727-746.	4.6	7
790	The utility of chest ultrasound-guided fine-needle biopsy in the diagnosis of plasmacytoma. African Journal of Thoracic and Critical Care Medicine, 0, , 167-171.	0.6	1
791	Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment. Blood Cancer Journal, 2023, 13, .	6.2	8
792	Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice. International Journal of Hematology, 0, , .	1.6	1
793	Primary Plasma Cell Leukemia. , 2023, 1, .		0